5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
The numbers didn't lie: Gilead Sciences (NASDAQ: GILD) posted pretty good second-quarter results. While revenue and earnings fell compared to the prior-year period, the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better-than-expected performance from its hepatitis C virus (HCV) franchise. Gilead even upped its full-year 2017 guidance.
But any company's quarterly results are just a snapshot looking in the rearview mirror. They don't reveal everything investors need to know about where a company is headed.
However, management sometimes provides a few clues in the earnings conference call that can hepatitis investors get a better feel for what could be in store. With that in mind, here are five things Gilead Sciences' second-quarter earnings numbers didn't tell you -- but for which the biotech's management shared some insight. (Quotes courtesy of S&P Global Market Intelligence.)
Source: Fool.com
GSK plc ADR Aktie
Die Community bevorzugt GSK plc ADR mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein Kursziel von 49 € für GSK plc ADR würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 36.0 € bedeuten.
